Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.
Caballero-Velázquez T, Pérez-López O, Yeguas Bermejo A, Rodríguez Arbolí E, Colado Varela E, Sempere Talens A, Vidriales MB, Solé-Rodríguez M, Quirós Caso C, Pérez López E, Reinoso Segura M, Prats-Martín C, Montesinos P, Pérez-Simón JA.
Caballero-Velázquez T, et al. Among authors: prats martin c.
Cancers (Basel). 2023 Mar 5;15(5):1609. doi: 10.3390/cancers15051609.
Cancers (Basel). 2023.
PMID: 36900400
Free PMC article.